Lu sur : https://www.ncbi.nlm.nih.gov/pubmed/30443340
Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en
F1000Res. 2018 Oct 31;7. pii: F1000 Faculty Rev-1727. doi: 10.12688/f1000research.15973.1. eCollection 2018.
Recent advances in understanding and managing myasthenia gravis.
Jordan A1, Freimer M1.
Autoimmune myasthenia gravis (MG) is a neuromuscular junction disorder marked clinically by fatigable muscle weakness and serologically by the presence of autoantibodies against acetylcholine receptors (AChRs), muscle-specific kinase (MuSK), or lipoprotein-related protein 4 (LPR4).
Over the past few decades, the mortality of patients with MG has seen a dramatic decline secondary to evolving interventions in critical care and medical management.
In the past 2 to 3 years, there have been several changes in standard of care for the treatment of MG.
These changes include confirmation of the benefit of thymectomy versus medical management alone in AChR patients and a new US Food and Drug Administration-approved medication for refractory MG.
There are also several exciting new prospective drugs in the pipeline, which are in different stages of clinical trial testing.
La traduction en français de l'article intégral est ICI